falsefalse

Targeting the PI3K/AKT/PTEN Pathway in HR+/HER2- Locally Advanced and Metastatic Breast Cancer - Episode 1

Biomarker Testing Best Practices in HR+/HER2- Locally Advanced or Metastatic Breast Cancer

,

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PIK3CA alterations, AKT1 alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Biomarker Testing Best Practices in HR+/HER2- Locally Advanced or Metastatic Breast Cancer
    EP. 2: First-Line Treatment Options in HR+/HER2- Locally Advanced and Metastatic Breast Cancer and Challenges with Treatment Resistance
    EP. 3: Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway
    EP. 4: Clinical Decision Making to Overcome Treatment Resistance in 2L HR+/HER2- Locally Advanced or Metastatic Breast Cancer
    EP. 5: Targeted Therapies in HR+/HER2- Locally Advanced or Metastatic Breast Cancer: CAPItello-291
    EP. 6: Other Trials of Note Investigating Targeted Therapies in Later-line HR+/HER2- Locally Advanced or Metastatic Breast Cancer
    EP. 7: Adverse Event Monitoring and Management in HR+/HER2- Locally Advanced and Metastatic Breast Cancer
    EP. 8: Emerging Trials in the Management of HR+/HER2- Locally Advanced or Metastatic Breast Cancer

    Related Content:

    Targeting the PI3K/AKT/PTEN Pathway in HR+/HER2- Locally Advanced and Metastatic Breast CancerUPMC Hillman Cancer CenterSarah Cannon Research InstituteClinicalBreast CancerInsightsVideo Series
    Fertility and Toxicity Considerations Factor into TNBC Management
    Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC
    T-DXd/Pertuzumab Yields PFS Benefit vs THP in HER2+ Metastatic Breast Cancer
    x